The rollout of the COVID-19 vaccines is gaining momentum, and has the potential to help the global population move beyond the current pandemic, however, there is the potential for the rollout to impact clinical trials. In this webinar, we will look at the challenges of continuing clinical trials during the rollout period to produce reliable data, while also maintaining the health and safety of participants as the number one priority.
As the vaccine rollout continues, it is anticipated that it will have an effect on completion levels for clinical trial participants, particularly where any medical indications from the vaccine may mask or be attributed to the pharmaceutical being studied.
By increasing communication channels and frequency, as well as developing strategies around crossover trials and offering alternative locations with different vaccine rollout stages in the population, much of these challenges can be addressed.
This webinar shows how Nucleus Network is meeting this challenge, and how it can assist or complement clients conducting trials at this time.
Key Learning Objectives
- Prioritising participant health and safety without compromising ongoing trials
- Expanding communication channels and frequency
- Selecting specific clinic sites to prefer vaccinated or naive
- Protocol considerations to accommodate vaccination rollout
